Document Detail

Breaking the Aggregation of the Monoclonal Antibody Bevacizumab (Avastin®) by Dexamethasone Phosphate: Insights from Molecular Modelling and Asymmetrical Flow Field-Flow Fractionation.
MedLine Citation:
PMID:  23412914     Owner:  NLM     Status:  Publisher    
PURPOSE: To investigate the mechanism behind the aggregation breaking properties of dexamethasone phosphate and related corticosteroids on the IgG1 antibody bevacizumab (Avastin®). METHODS: An in silico 3D dimer model is developed to identify the bevacizumab-bevacizumab interface, and different corticosteroids are docked onto the model to distinguish preferred binding sites. In silico predictions are validated by in vitro stability studies, where the antibody is stressed in presence or absence of each corticosteroid and formed aggregates are quantified by asymmetrical flow field-flow fractionation. RESULTS: The dimer model features one close crystal contact area: Lys445 on the Fc region interacts with one Fab arm of the second bevacizumab. Docking reveals an interaction between the phosphate group of dexamethasone phosphate and Lys445, while the rest of the molecule is hindering dimer formation. Predictions are confirmed in vitro, demonstrating that dexamethasone phosphate and betamethasone phosphate partly prevent antibody aggregation, whereas triamcinolone acetonide phosphate does not. CONCLUSIONS: Results suggest that bevacizumab monomers follow a specific mechanism to form dimers in which a protein-protein interaction hotspot can be distinguished. The dimer formation can be hindered by corticosteroids in a specific way. This approach allows a simple way to stabilize IgG1 antibodies.
Marieke Veurink; Yvonne Westermaier; Robert Gurny; Leonardo Scapozza
Related Documents :
6173324 - Polypeptides and functions of antigens from human coronaviruses 229e and oc43.
23412914 - Breaking the aggregation of the monoclonal antibody bevacizumab (avastin®) by dexametha...
7519264 - Changes in cytokeratins following treatment of hamster cheek pouch epithelia with hyper...
8961644 - Antibody immunoglobulin g (igg) response to alouattamyia baeri (diptera:cuterebridae) p...
24237694 - Tlr5 stops commensals in their tracks.
20451984 - Human ige antibody serology: a primer for the practicing north american allergist/immun...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-2-15
Journal Detail:
Title:  Pharmaceutical research     Volume:  -     ISSN:  1573-904X     ISO Abbreviation:  Pharm. Res.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-2-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8406521     Medline TA:  Pharm Res     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Detecting sequence homology at the gene cluster level with MultiGeneBlast.
Next Document:  Fluorogenic Tagging Methodology Applied to Characterize Oxidized Tyrosine and Phenylalanine in an Im...